SPRAVATO | Shining Family

SPRAVATO
(Esketamine Nasal Spray) for Depression

Some patients with depression may not experience sufficient relief from conventional antidepressant medications.

In view of this, our centre offers SPRAVATO® nasal spray therapy, which is suitable for adult patients who have tried at least two different antidepressants without adequate improvement, as well as adults with depression who are experiencing significant or acute suicidal thoughts or behavior.

Benefit

Patients using SPRAVATO® together with oral antidepressants may experience improvement in depressive symptoms within 24 hours
More than 50% of patients reached remission by Day 28
58.2% remained in remission after one year.
Among patients with a stable response, SPRAVATO® was associated with a 70% lower risk of relapse over the long term.

Book a consultation to learn more

Treatment Principle

Unlike traditional antidepressants that target the monoamine system, SPRAVATO® nasal spray therapy works through a new antidepressant mechanism that targets the glutamate system.

It helps strengthen connections between brain neurons and may restore dopamine signaling in brain regions involved in reward learning, leading to a faster antidepressant effect.

Who Is It Suitable For?

Adult patients who have tried at least two different antidepressants without adequate improvement.
Adult patients with depression who are experiencing significant or acute suicidal thoughts or behavior.

Eligible Patients

Who Is It Not Suitable For?

Patients with any cardiovascular disease.
Patients who are allergic to any ingredient in this medication.
Patients for whom an increase in blood pressure or intracranial pressure may pose a serious risk, including those with aneurysm, cerebral hemorrhage, or a recent heart attack within the past 6 weeks.
Pregnant women.
Patients with a history of psychotic disorders, such as delusions or hallucinations.
Patients with a history of bipolar disorder or manic symptoms.

Not Suitable For

If you have any other physical or mental health conditions, please inform your psychiatrist and discuss them in detail

Heart problems that are difficult to control, such as poor blood flow in the heart vessels often accompanied by chest pain (e.g. angina), high blood pressure, heart valve disease, or heart failure
A history of slow or fast heartbeat that caused shortness of breath, palpitations, chest discomfort, dizziness, or fainting
A history of problems with blood supply to the brain, such as stroke
A history of severe head injury or serious brain conditions, especially if associated with increased pressure in the brain
A history of substance misuse, including prescription drugs, illegal drugs, or alcohol misuse
Untreated hyperthyroidism
Lung disease that causes breathing difficulties, including chronic obstructive pulmonary disease (COPD)
Sleep apnea and severe obesity
Severe liver disease

A calm, safe, and relaxing treatment environment

Find Out If This Treatment Is Right for You

Treatment Process

This treatment must be carried out at the centre
under the supervision of medical staff.

Medical staff will explain how to use the nasal spray, as well as the possible side effects and precautions.

Blood pressure will be measured before treatment to ensure it is stable.

The patient will be guided through the medication process.

After each device is used, the patient should rest in a comfortable position, preferably semi-reclined, for 5 minutes.

Blood pressure will be checked again every 15 minutes after dosing.

After completing the treatment, the patient will remain at the clinic for 2 hours. If medically assessed as clinically stable, they may then leave.

Treatment and Dosage

Standard course: Use twice per week for 4 weeks, for a total of 8 treatment sessions.

Dosage per session: 2–3 doses are required for each treatment session.

First Month (Introduction Phase)

Twice weekly treatment, 56 mg per session (2 devices) / 84 mg per session (3 devices).

Second Month (Maintenance Phase)

Receive treatment once per week.Each session is 56 mg (2 devices) or 84 mg (3 devices).

Third Month

Treatment is given once a week or once every two weeks.
Each session is 56 mg (2 devices) or 84 mg (3 devices).

If needed, the doctor may increase or decrease the dose for each treatment session according to the patient’s condition.
Patients 65 years and older may require 28 mg (1 device), which is used only on Day 1 of the introductory phase.
If one or two sessions are missed, the patient should schedule the next session according to the current treatment frequency.
If more than two sessions are missed, the doctor may need to adjust the Spravato dose or treatment frequency based on clinical judgment.

Side Effects

Common side effects

Dizziness (38.3%)
Dissociation (33.9%)
Nausea (26.9%)
Somnolence (20.7%)
Dysgeusia (19.8%)
Blurred vision (11.9%)
Increased blood pressure (11.5%)

**Most side effects typically peak at around 40 minutes after administration. They are generally temporary and usually last for approximately 1–2 hours.

More About Depression

揀玩具都有學問：跟住能力玩出語言力

Speech therapist Phrixus Ip shares tips on selecting age-appropriate toys and language strategies based on a child's play skills and development stage, helping them naturally express themselves during play.

認可名冊言語治療師葉潤航教路，三個遊戲小技巧，讓孩子邊玩邊講，輕鬆提升說話能力。

玩住學講嘢｜3個日常家居遊戲幫助幼兒語言發展｜言語治療師

Speech therapist Phrixus Ip shares three simple game tips to help children talk while they play and build speaking skills more naturally.

我係咪有焦慮症/強迫症？一句話教你分清楚：係壓力定係病！網上自測準唔準？點解強迫症要食重藥？精神科專科黃穎勤醫生解答焦慮症3大迷思

焦慮症強迫症難自控？

Constantly washing hands out of fear of bacterial infection, repeatedly checking if doors and windows are locked before going out, or persistently holding negative thoughts about the future— are these normal reactions under stress, or signals of anxiety disorder or OCD? Psychiatrist Dr. Wong Wing-kun points out, "To determine if someone has anxiety disorder or OCD, it depends on whether the symptoms severely impact daily life, such as insomnia, loss of appetite, chronic heada

2 3 4 5

Learn More About SPRAVATO

SPRAVATO (Esketamine Nasal Spray) for Depression

Benefit

Patients using SPRAVATO® together with oral antidepressants may experience improvement in depressive symptoms within 24 hours

More than 50% of patients reached remission by Day 28

58.2% remained in remission after one year.

Among patients with a stable response, SPRAVATO® was associated with a 70% lower risk of relapse over the long term.

Treatment Principle

Who Is It Suitable For?

Adult patients who have tried at least two different antidepressants without adequate improvement.

Adult patients with depression who are experiencing significant or acute suicidal thoughts or behavior.

Eligible Patients

Who Is It Not Suitable For?

Patients with any cardiovascular disease.

Patients who are allergic to any ingredient in this medication.

Patients for whom an increase in blood pressure or intracranial pressure may pose a serious risk, including those with aneurysm, cerebral hemorrhage, or a recent heart attack within the past 6 weeks.

Pregnant women.

Patients with a history of psychotic disorders, such as delusions or hallucinations.

Patients with a history of bipolar disorder or manic symptoms.

Not Suitable For

If you have any other physical or mental health conditions, please inform your psychiatrist and discuss them in detail

Heart problems that are difficult to control, such as poor blood flow in the heart vessels often accompanied by chest pain (e.g. angina), high blood pressure, heart valve disease, or heart failure

A history of slow or fast heartbeat that caused shortness of breath, palpitations, chest discomfort, dizziness, or fainting

A history of problems with blood supply to the brain, such as stroke

A history of severe head injury or serious brain conditions, especially if associated with increased pressure in the brain

A history of substance misuse, including prescription drugs, illegal drugs, or alcohol misuse

Untreated hyperthyroidism

Lung disease that causes breathing difficulties, including chronic obstructive pulmonary disease (COPD)

Sleep apnea and severe obesity

Severe liver disease

A calm, safe, and relaxing treatment environment

Treatment Process

This treatment must be carried out at the centre under the supervision of medical staff.

Medical staff will explain how to use the nasal spray, as well as the possible side effects and precautions.

Blood pressure will be measured before treatment to ensure it is stable.

The patient will be guided through the medication process.

After each device is used, the patient should rest in a comfortable position, preferably semi-reclined, for 5 minutes.

Blood pressure will be checked again every 15 minutes after dosing.

After completing the treatment, the patient will remain at the clinic for 2 hours. If medically assessed as clinically stable, they may then leave.

Treatment and Dosage

Standard course: Use twice per week for 4 weeks, for a total of 8 treatment sessions. Dosage per session: 2–3 doses are required for each treatment session.

First Month (Introduction Phase)

Twice weekly treatment, 56 mg per session (2 devices) / 84 mg per session (3 devices).

Second Month (Maintenance Phase)

Receive treatment once per week.Each session is 56 mg (2 devices) or 84 mg (3 devices).

Third Month

Treatment is given once a week or once every two weeks. Each session is 56 mg (2 devices) or 84 mg (3 devices).

If needed, the doctor may increase or decrease the dose for each treatment session according to the patient’s condition.

Patients 65 years and older may require 28 mg (1 device), which is used only on Day 1 of the introductory phase.

If one or two sessions are missed, the patient should schedule the next session according to the current treatment frequency.

If more than two sessions are missed, the doctor may need to adjust the Spravato dose or treatment frequency based on clinical judgment.

Side Effects

Common side effects

​​

Dizziness (38.3%)

Dissociation (33.9%)

Nausea (26.9%)

Somnolence (20.7%)

Dysgeusia (19.8%)

Blurred vision (11.9%)

Increased blood pressure (11.5%) **Most side effects typically peak at around 40 minutes after administration. They are generally temporary and usually last for approximately 1–2 hours.